Dr Sanjiv Agarwala analyzes data from 2 studies showing that the first-line combination of nivolumab plus ipilimumab demonstrates deep and sustained confirmed responses, as well as improved overall survival compared with monotherapy, in patients with metastatic uveal melanoma.